Cesium carbonate → 5-(2,6-difluorophenyl)-3-{[1-(ethylsulphonyl)piperidin-4-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazolo[4,3-c]isoquinoline-7-carbaldehyde

HRID 1256248Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1256248
Br[C:2]1[N:3]([CH2:25][O:26][CH2:27][CH2:28][Si:29]([CH3:32])([CH3:31])[CH3:30])[N:4]=[C:5]2[C:14]3[CH:13]=[CH:12][C:11]([CH:15]=[O:16])=[CH:10][C:9]=3[C:8]([C:17]3[C:22]([F:23])=[CH:21][CH:20]=[CH:19][C:18]=3[F:24])=[N:7][C:6]=12.[CH2:33]([S:35]([N:38]1[CH2:43][CH2:42][CH:41]([NH2:44])[CH2:40][CH2:39]1)(=[O:37])=[O:36])[CH3:34].C(=O)([O-])[O-].[Cs+].[Cs+].CC1(C)C2C=CC=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=2OC2C1=CC=CC=2P(C1C=CC=CC=1)C1C=CC=CC=1>O1CCOCC1.C([O-])(=O)C.[Pd+2].C([O-])(=O)C.O>[F:24][C:18]1[CH:19]=[CH:20][CH:21]=[C:22]([F:23])[C:17]=1[C:8]1[C:9]2[CH:10]=[C:11]([CH:15]=[O:16])[CH:12]=[CH:13][C:14]=2[C:2]2[N:3]([CH2:25][O:26][CH2:27][CH2:28][Si:29]([CH3:30])([CH3:31])[CH3:32])[N:4]=[C:5]([NH:44][CH:41]3[CH2:42][CH2:43][N:38]([S:35]([CH2:33][CH3:34])(=[O:36])=[O:37])[CH2:39][CH2:40]3)[C:6]=2[N:7]=1

Komponenten

8

Edukt 4

HCID 10796Cesium carbonateHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 167761864-Amino-1-ethanesulfonylpiperidineHCID 866649343-bromo-5-(2,6-difluorophenyl)-2-(2-trimethylsilanylethoxymethyl)-2H-pyrazolo[4,3-c]isoquinoline-7-carbaldehyde

Produkt 1

HCID 866649335-(2,6-difluorophenyl)-3-{[1-(ethylsulphonyl)piperidin-4-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazolo[4,3-c]isoquinoline-7-carbaldehydeAusbeute 45,9 %

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 167845palladium(II) acetateKatalysatorHCID 962WaterLösungsmittelHCID 312751,4-DioxaneLösungsmittel

Versuchsvorschrift

A 50 ml three-necked flask equipped with a magnetic stirrer and with an argon intake is charged with 350 mg of 3-bromo-5-(2,6-difluorophenyl)-2-(2-trimethylsilanylethoxymethyl)-2H-pyrazolo[4,3-c]isoquinoline-7-carbaldehyde, prepared in step 5 of example 2, in 7.8 ml of 1,4-dioxane. 195 mg of 1-ethylsulphonylpiperidin-4-ylamine, 880 mg of caesium carbonate, 59 mg of 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene and 15 mg of palladium(II) acetate are added. The mixture is heated at reflux for 2 h. After cooling, the mixture is poured into water and extracted with AcOEt. The organic phase is washed with saturated NaCl solution, dried over MgSO4, filtered and concentrated under RP. It is purified by flash chromatography on silica gel (15-40 μm), eluting with a mixture of cyclohexane and AcOEt (75/25 by vol.), to give 195 mg of 5-(2,6-difluorophenyl)-3-{[1-(ethylsulphonyl)piperidin-4-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazolo[4,3-c]isoquinoline-7-carbaldehyde (yellow foam). LC-MS-DAD-ELSD 628=(M−H)(+).

Aufarbeitung

  1. customA 50 ml three-necked flask equipped with a magnetic stirrer and with an argon intake
  2. temperatureThe mixture is heated
  3. temperatureat reflux for 2 h
  4. temperatureAfter cooling
  5. extractionextracted with AcOEt
  6. washThe organic phase is washed with saturated NaCl solution
  7. dry with materialdried over MgSO4
  8. filtrationfiltered
  9. concentrationconcentrated under RP
  10. customIt is purified by flash chromatography on silica gel (15-40 μm)
  11. washeluting with a mixture of cyclohexane and AcOEt (75/25 by vol.)

Quellen und Nachweise

ORD-Eintrag
ord-2ac1086e98694ff58ad9eb09df1756fe
Quelldatensatz
uspto-grants-2013_06
Patentnummer
US08461175B2

Notizen zur Reaktion

Wird geladen…